Mammaglobin-A DNA Vaccine

Phase 1Vaccine

WWashington University School of Medicine

Mammaglobin-A DNA Vaccine is one of 28 biologic programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

721 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 2

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 3

Tianeptine

Pfizer

Preclinical

1 4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Mammaglobin-A DNA Vaccine

WWashington University School of Medicine

Phase 1

2 6

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 7

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 8

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Active, not recruiting

Breast Cancer

NCT02204098

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT02204098·27 enrolled

Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer

Completed·WWashington University School of Medicine·Phase 1·NCT00807781·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mammaglobin-A DNA Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mammaglobin-A DNA Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mammaglobin-A DNA Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: WWashington University School of Medicine

Mammaglobin-A DNA Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Breast Cancer2 trials

References

Drug Info

Quick Facts

Related News